Hormone Therapy in Prostate Cancer: LHRH Antagonists versus LHRH Analogues

Fluker, 2000, Gonadotropin-releasing hormone antagonists, Curr. Opin. Endocrinol. Diabetes, 7, 350, 10.1097/00060793-200012000-00010 Tomera K, Gleason D, Gittleman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB for the abarelix study group. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001;165:1585–9. McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, Garnick MB for the abarelix study group. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58:756–61. Stricker, 2001, Luteinizing hormone-releasing hormone antagonists in prostate cancer, Urology, 58, 24, 10.1016/S0090-4295(01)01238-9 Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, Fotheringham N, Campion M, Garnick MB and the abarelix study group. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002;167:1670–4. Hurkadli, 1990, Immunocytochemical localisation of follicle stimulating hormone (FSH) in normal, benign and malignant human prostates, Br. J. Cancer, 61, 225, 10.1038/bjc.1990.42 Garde, 1991, Prostate—an extrapituitary source of follicle-stimulating hormone (FSH): occurrence, localization, and de novo biosynthesis and its hormonal modulation in primates and rodents, Prostate, 18, 271, 10.1002/pros.2990180402 Ben-Josef, 1999, Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR), J. Urol., 161, 970, 10.1016/S0022-5347(01)61831-7 Mahler, 1991, Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue, Cancer, 67, 557, 10.1002/1097-0142(19910201)67:3<557::AID-CNCR2820670304>3.0.CO;2-C Beer, 2003, Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy, J. Urol., 169, 1738, 10.1097/01.ju.0000059584.47272.9d Bracci, 1977, Hormonal pattern in prostatic carcinoma following orchidectomy: 5-year follow-up, Br. J. Urol., 49, 161, 10.1111/j.1464-410X.1977.tb04092.x Huhtaniemi, 1988, Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy, J. Clin. Endocrinol. Metab., 66, 308, 10.1210/jcem-66-2-308 Beer, 2004, Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy, Urology, 63, 342, 10.1016/j.urology.2003.09.045 Tao, 1997, Expression of luteinizing hormone/human chorionic gonadotropin receptor gene in benign prostatic hyperplasia and in prostate carcinoma in humans, Biol. Reprod., 56, 67, 10.1095/biolreprod56.1.67 Dirnhofer, 1998, Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate, Prostate, 35, 212, 10.1002/(SICI)1097-0045(19980515)35:3<212::AID-PROS7>3.0.CO;2-I Bono, 2002, Gonadotropin-releasing hormone receptors in prostate tissue, Anal. Quant. Cytol. Histol., 24, 221 Bahk, 1998, Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells, Urol. Res., 26, 259, 10.1007/s002400050054 Lamharzi, 1998, Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice, Int. J. Oncol., 13, 429 Lamharzi, 1998, Luteinizing hormone-releasing hormone (LH-RH) antagonist cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors, Regul. Pept., 77, 185, 10.1016/S0167-0115(98)00119-0 Gonzalez-Barcena, 1995, Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord, Urology, 45, 275, 10.1016/0090-4295(95)80018-2 Koch M, Steidle C, Brosman S, Centeno A, Gaylis F, Campion M, Garnick MB for the abarelix study group. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. Urology 2003;62:877–82. Sartor, 2003, Eligard: leuprolide acetate in a novel sustained-release delivery system, Urology, 61, 25, 10.1016/S0090-4295(02)02396-8 Sharifi R, Browneller R and the leuprolide study group. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol 2002;168:1001–4.